SCHEDULE: Armistice Capital Discloses 8.7% Stake in Acurx Pharma

Armistice Capital and Steven Boyd have disclosed a passive 8.7% beneficial ownership stake in Acurx Pharmaceuticals, Inc. common stock.

Summary

• Armistice Capital, LLC and Steven Boyd collectively reported beneficial ownership of 2,917,975 shares of Acurx Pharmaceuticals, Inc. Common Stock.
• This ownership represents 8.70% of the issuer's outstanding common stock.
• The shares are held with shared voting power and shared dispositive power by both Armistice Capital, LLC and Steven Boyd.
• Armistice Capital, LLC, a Delaware entity, acts as the investment manager for Armistice Capital Master Fund Ltd., the direct holder of the shares.
• Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC.
• The acquisition of these securities was made in the ordinary course of business and not for the purpose of changing or influencing the control of Acurx Pharmaceuticals, Inc.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or prospects.

Positives

• NA

Negatives

• NA

Risks

• NA

Future Outlook

NA

Management Comments

• The securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This filing is a disclosure of a significant ownership stake by an investment firm in a pharmaceutical company. It does not provide broader industry trends or competitive analysis.

Related Party Transactions

• Armistice Capital Master Fund Ltd., a Cayman Islands exempted company and an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.

Stakeholder Impact

• Shareholders: Disclosure of a significant 8.70% stake by an institutional investor may influence market perception and trading activity for Acurx Pharmaceuticals, Inc. common stock.

Key Dates

Keywords

Acurx Pharmaceuticals, Armistice Capital, Steven Boyd, Beneficial Ownership, Common Stock, SEC Filing, Schedule 13G, Investment Management, Pharmaceuticals